Nivolumab Superior to Ipilimumab for Melanoma Recurrence Prevention
The randomized phase 3 CheckMate 238 trial evaluated the safety and efficacy of nivolumab vs ipilimumab in the resected stage III/IV melanoma setting.
ESMO 2017
Lenvatinib May Delay Functional Deterioration in Hepatocellular Carcinoma
Patients had similar HRQOL scores by all measures at baseline, but experienced significant changes in scores for the HRQOL domains of Body Image, Diarrhea, Nutrition, Pain, and Role Function.
Liquid Biopsies Are Highly Sensitive for Actionable Mutations in Solid Tumors
Alterations conferring resistance to targeted agents were identified among 18% of samples from NSCLC, breast, colorectal, and prostate cancers, melanoma, and gastrointestinal stromal tumors.
No Difference in Survival With CT Scan at Follow-ups for Resected NSCLC
Although these data did not demonstrate improved survival with the inclusion of a CT scan at routine follow-up visits, the authors noted that a longer follow-up time is necessary to identify any long-term OS benefits.
Durvalumab May Prolong PFS in Non-small Cell Lung Cancer After Chemoradiation
Researchers randomly assigned 713 patients with NSCLC who did not progress after 2 or more cycles of platinum-based concurrent chemoradiation therapy to receive durvalumab 10 mg/kg consolidation therapy or placebo for up to 12 months.
Initial Abemaciclib Improves PFS and ORR in Advanced Breast Cancer
Researchers compared the efficacy of abemaciclib plus anastrozole or letrozole vs placebo plus anastrozole or letrozole among patients not previously treated with a systemic therapy.
TILs May Predict Pembrolizumab Response in Triple-negative Breast Cancer
The results of the study demonstrate that increased TIL levels may be associated with a greater response to pembrolizumab monotherapy in patients with mTNBC, especially in the first-line setting.
Osimertinib Shows Promise As A First-line Therapy in EGFRm NSCLC
Patients who received osimertinib had a PFS of 18.9 months compared with 10.2 months among those who received SoC treatments (P < .0001).
Two Additions to Standard of Care in Prostate Cancer May Improve Outcomes
Long-term hormone monotherapy has been the standard of care for patients with PCa for more than 60 years. The purpose of this study was to compare the efficacy of 2 new treatment standards using a patient subset of the STAMPEDE trial.
Atezolizumab Improves Overall Survival Regardless of PD-L1 Expression in NSCLC
The phase 3 OAK trial demonstrated that previously treated patients with advanced NSCLC experienced prolonged OS with atezolizumab compared to docetaxel regardless of PD-L1 status.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in ESMO 2017
Loading... 
Loading...